In 2011, ipilimumab became the first approved blockade agent targeting the T-cell inhibitory receptor “cytotoxic T-lymphocyte antigen-4” (CTLA-4); advanced melanoma patients treated with ipilimumab demonstrated improved tumor control and survival (11). The gene discussed is CTLA4; the disease is neoplasm.